June 9, 2021

Lessons Learned from the Biopharma Industry's Response to the COVID-19 Pandemic


James Blackwell, President, Windshire Group, LLC, discusses the biopharma industry’s response to the COVID-19 pandemic and how lessons learned can be applied to improve process development for non-pandemic development programs.

Topic covered include:

1:38 – The typical time frame for process design and process qualification for a biopharmaceutical development program

2:10 – The driving forces for the rapid scale up of production of vaccines and therapies

2:31 – The role that influx of financial investment (government and private) played in advancing process development

3:44 – Technologies that contribute to accelerated process development

6:36 – The role of equipment and material suppliers in expediting process development

9:40 – The industry’s adoption of more rapid process development approaches

10:47 – The future of “manufacturing at risk” in the industry

11:29 – Lessons/insight that the pandemic experience revealed about traditional process development methods that can contribute to improvements for non-pandemic drug development applications

Related Content

Q&As with Industry Leaders 

Tags: manufacturing, vaccines, process development, COVID-19